Concerns about tablet-splitting of muscle relaxant

23 May 2004

Back and neck pain sufferers who divide the most frequently-prescribed muscle relaxant may be getting anywhere from half to one-and-a-half times the amount of medicine they believe they are taking, suggests a new study examining the practice of tablet-splitting. This may place them at an increased risk of encountering side effects such as drowsiness and fatigue from too much medication, according to the study's primary investigator.

Researchers at the Ernest Mario School of Pharmacy at Rutgers, the State University of New Jersey, recently conducted a study to determine the level of weight variability of tablet fragments when the muscle relaxant cyclobenzaprine HCl 10mg was split into halves with two commonly-used devices - a tablet splitter and a kitchen knife.

Initiation of the study followed anecdotal reports that patients given a prescription for branded Flexeril (cyclobenzaprine HCl) 5mg tablets were being advised to split generic cyclobenzaprine HCl 10mg tablets instead of taking the 5mg tablet as prescribed by their physician. Flexeril 5mg, approved by the US Food and Drug Administration in February 2003, is comparable in efficacy to the 10mg strength, but has been shown to be less sedating.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight